Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case–control study by Byrne, Celia et al.
 
Benign breast disease, recent alcohol consumption, and risk of
breast cancer: a nested case–control study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Tamimi, Rulla M, Celia Byrne, Heather J Baer, Bernie Rosner,
Stuart J Schnitt, James L Connolly, and Graham A Colditz. 2005.
Benign breast disease, recent alcohol consumption, and risk of
breast cancer: a nested case-  control study. Breast Cancer
Research 7(4): R555-R562.
Published Version doi://10.1186/bcr1039
Accessed February 19, 2015 8:25:59 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874589
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAOpen Access
Available online http://breast-cancer-research.com/content/7/4/R555
R555
Vol 7 No 4 Research article
Benign breast disease, recent alcohol consumption, and risk of 
breast cancer: a nested case–control study
Rulla M Tamimi1,2, Celia Byrne3, Heather J Baer1,2, Bernie Rosner1,4, Stuart J Schnitt5, 
James L Connolly5 and Graham A Colditz1,2,6
1Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
3Cancer Genetics and Epidemiology Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
4Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
5Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
6Harvard Center for Cancer Prevention, Boston, MA, USA
Corresponding author: Rulla M Tamimi, rulla.tamimi@channing.harvard.edu
Received: 7 Jan 2005 Revisions requested: 31 Jan 2005 Revisions received: 8 Mar 2005 Accepted: 12 Apr 2005 Published: 16 May 2005
Breast Cancer Research 2005, 7:R555-R562 (DOI 10.1186/bcr1039)
This article is online at: http://breast-cancer-research.com/content/7/4/R555
© 2005 Tamimi et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Alcohol consumption is a well-established risk
factor for breast cancer. Some studies have suggested that the
risk of breast cancer associated with alcohol consumption is
greater for women with a history of benign breast disease
(BBD). We hypothesized that among women with biopsy-
confirmed BBD, recent alcohol consumption would increase the
risk of breast cancer in women with proliferative breast disease
to a greater extent than in women with nonproliferative breast
disease.
Methods We conducted a nested case–control study in the
Nurses' Health Study I and II. The cases (n = 282) were women
diagnosed with incident breast cancer, with a prior biopsy-
confirmed breast disease. The controls (n  = 1,223) were
participants with a previous BBD biopsy, but without a
diagnosis of breast cancer. Pathologists reviewed benign breast
biopsy slides in a blinded fashion and classified the BBD as
nonproliferative, proliferative without atypia, or atypical
hyperplasia, according to standard criteria.
Results Women with nonproliferative breast disease
consuming ≥  15 g of alcohol per day had a nonsignificant 67%
increased risk of breast cancer (odds ratio = 1.67; 95%
confidence interval 0.65 to 4.34) compared with nondrinkers.
There was no evidence that recent alcohol consumption
increased the risk of breast cancer to a greater extent in women
with proliferative BBD than among women with nonproliferative
BBD (P for interactio n = 0.20).
Conclusion Contrary to our a priori hypothesis, there was no
evidence that recent alcohol consumption increased the risk of
breast cancer to a greater extent among women with
proliferative BBD than among women with nonproliferative
BBD.
Introduction
Alcohol consumption is a well-established risk factor for breast
cancer. Among those who drink, recent alcohol consumption
of two or more drinks a day is associated with an approxi-
mately 30% increased risk of breast cancer compared with
nondrinkers [1-3]. A pooled analysis of over 32,000 women
participating in six prospective cohort studies [1], and at least
three meta-analyses [2,4,5], confirmed that risk of breast can-
cer increases monotonically with increasing alcohol consump-
tion [1,2].
Data from epidemiologic studies also suggest that alcohol
may influence early stages as well as later stages of breast car-
cinogenesis. The primary evidence that alcohol may have an
effect on early stages in the carcinogenic process comes
largely from studies of alcohol consumption and mammo-
graphic density. Breast density is a strong predictor of breast
cancer risk and is considered to be an early biomarker of
breast cancer [6-9]. In most studies, recent alcohol consump-
tion is positively associated with mammographic density [10-
12]. Recent alcohol consumption has not been associated
BBD = benign breast disease; CI = confidence interval; NHS (I, II) = Nurses' Health Study (I, II); OR = odds ratio; RR = relative risk.Breast Cancer Research    Vol 7 No 4    Tamimi et al.
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with increased incidence of proliferative benign breast disease
(BBD) [13-15], although alcohol consumption between the
ages of 18 and 22 has been associated with an increased risk
of proliferative breast disease in one study [13].
A few studies have suggested that the increased risk of breast
cancer associated with alcohol consumption is greater for
women with a history of BBD [16,17], although the interac-
tions were not statistically significant and this relation has not
been observed in all studies [18]. BBD comprises multiple his-
tologic subtypes. In prospective studies, where investigators
have examined the risk associated with histologic subtypes of
BBD, the proliferative lesions and in particular those with aty-
pia were associated with the highest risk [19-21]. We hypoth-
esized that among women with biopsy-confirmed BBD,
alcohol consumption would increase the risk of breast cancer
in those with proliferative breast disease to a greater extent
than in women with nonproliferative breast disease.
Materials and methods
Study population
The Nurses' Health Study (NHS I) cohort was initiated in
1976, when 121,700 US registered nurses ages 30 to 55
returned an initial questionnaire. The Nurses' Health Study II
(NHS II) is also an ongoing cohort study of over 116,000 US
female nurses who were 25 to 42 years of age in 1989 when
the study was initiated. Every 2 years, information on reproduc-
tive variables, body mass index, exogenous hormone use, and
disease outcomes is collected in both cohorts. Semiquantita-
tive food frequency questionnaires were included as part of
the biennial questionnaire in 1980, 1984, 1986, and 1990 in
NHS I, and in 1991 in NHS II. Alcohol consumption was also
assessed on the baseline 1989 questionnaire in NHS II. The
methods developed to follow up participants and confirm inci-
dent cancers and death in the Nurses' Health Study have been
described previously in detail elsewhere [22] and have been
applied to NHS II.
Benign breast disease
Beginning with the initial NHS I questionnaire in 1976, partic-
ipants have been asked on every biennial questionnaire to
report any diagnosis of fibrocystic disease or other BBD. Early
questionnaires (1976, 1978, and 1980) asked whether the
respondent had ever been diagnosed as having 'fibrocystic
disease' or 'other BBD' and whether she had been hospital-
ized with this diagnosis. Beginning in 1982, the NHS I ques-
tionnaires sought specific details of a history of biopsy-
confirmed BBD. The initial 1989 NHS II questionnaire and all
subsequent biennial questionnaires also asked participants to
report any diagnosis of BBD and to indicate if it was confirmed
by biopsy or aspiration.
Selection of breast cancer cases and controls
We conducted a case–control study nested within the subco-
hort of women with a biopsy-confirmed BBD. Incident breast
cancer cases in both cohorts were identified through the
nurses' own reports and were confirmed by review of medical
records. Cases in the study are cases of breast cancer diag-
nosed by 1 June 1994 (NHS I) or 1 June 1995 (NHS II) with a
previous confirmed BBD biopsy and available pathology spec-
imens (histologic sections and/or tissue blocks). Controls are
women who did not have a diagnosis of breast cancer when
the case was diagnosed and also had a previous biopsy-con-
firmed BBD and available pathology specimens. Controls
were matched to cases on year of birth and year of biopsy.
Attempts were made to identify four matched controls for each
case, although this was not always possible. This study was
approved by the Committee on Human Subjects at Brigham
and Women's Hospital.
We identified incident confirmed breast cancer cases diag-
nosed after the return of the initial questionnaire through the
1994/1995 follow-up cycle and controls that also reported a
previous biopsy-confirmed BBD. A total of 1,080 cases were
originally identified for this study, and 4,353 controls matched
on age and year of benign breast biopsy were selected. After
selection, 2.1% were found to be no longer eligible and were
excluded. Seventy-five percent of eligible participants con-
firmed their BBD biopsy and granted permission to review
their pathology slides. In response to our slide requests, we
received pathology specimens for 55% of the study subjects.
The primary reason given by pathology departments for not
sending slides or tissue blocks was that the specimens had
been destroyed or were no longer available (33%). There were
no significant differences in the success of obtaining slides for
breast cancer cases and controls. A detailed description of
the steps of specimen collection and exclusions of selected
cases and controls during the collection process are included
in Table 1. An additional 156 women were excluded for the fol-
lowing reasons: reported bilateral BBD, but tissue specimen
did not identify breast side (n = 2), report of breast cancer
either before study start or after the 1994/1995 follow-up
cycle (n = 10), and date of benign breast diagnosis was within
six months of the breast cancer diagnosis date (cases) or
index date (controls) (n = 144).
Pathology review
Slides were coded by a research assistant and submitted to
one of two collaborating pathologists (SJS, JLC) in a blinded
fashion. The pathologists independently reviewed the BBD
biopsy slides. Any slide identified as having either questiona-
ble atypia or atypia was jointly reviewed by the two patholo-
gists. For each set of slides reviewed, a detailed work sheet
was completed quantifying the extent of proliferative and atyp-
ical changes, morphologic features, and other details. BBDs
were classified according to the Page classification system
[23] into one of three categories: nonproliferative, proliferative
without atypia, and atypical hyperplasia. Upon pathology
review, it was determined that 29 women with an original BBD
diagnosis had evidence of carcinoma in situ (n  = 25) orAvailable online http://breast-cancer-research.com/content/7/4/R555
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invasive carcinoma (n = 4). These women were excluded from
further analysis. There were 353 breast cancer cases and
1,495 controls with pathology slides available from their BBD
biopsy.
Assessment of alcohol consumption
Information on alcohol consumption was obtained from semi-
quantitative food frequency questionnaires. In NHS I, ques-
tions regarding alcohol consumption were asked in 1980,
1984, 1986, and 1990. Women were asked about their aver-
age consumption of beer, wine, and liquor separately in the
prior year. One drink was considered equal to one can or bot-
tle of beer, a 4-ounce glass of wine, or one drink or shot of liq-
uor. Participants were asked to select from the following
categories: almost never, 1 to 3 per month, 1 per week, 2 to 4
per week, 5 to 6 per week, 1 per day, 2 to 3 per day, 4 to 6 per
day, 6 or more per day. Similarly, women in NHS II answered
questions on consumption of alcohol in the 1989 and 1991
questionnaires. In 1991, the NHS II alcohol questions were
expanded to include red wine, white wine, light beer, regular
beer, and liquor. Total alcohol consumption per questionnaire
cycle was calculated by adding the alcohol contributions from
beer, wine, and liquor. Grams of ethanol per day were calcu-
lated based on the following equivalents of 12.8 g for regular
beer, 11.3 g for light beer, 11.0 g for wine, and 14.0 g for liq-
uor. Alcohol consumption in NHS I has been shown to be valid
and highly reproducible in repeated assessments [24].
Women were assigned the alcohol exposure from the cycle
preceding the diagnosis of breast cancer. Cases and controls
in NHS I with diagnosis (or index) dates preceding the initial
food frequency questionnaire administered in 1980 were
excluded from the analysis (n = 36 cases, 129 controls). If
alcohol consumption was missing from the questionnaire
before the index date, the exposure from the preceding cycle
was assigned. The Spearman correlation between reported
alcohol consumption in questionnaire cycles was 0.80
(P<0.0001) or greater for all consecutive cycles. Women with
missing alcohol exposure data from two cycles preceding the
index date were excluded from the analyses (n = 35 cases,
143 controls). Thus, there were 282 patients with breast can-
cer and 1,223 controls eligible for this study with both BBD
pathology and detailed alcohol exposure preceding their index
date.
Analytic methods
Odds ratios (ORs) and 95% confidence intervals (CIs) were
determined using logistic regression models controlling for
matching factors (age, year of BBD biopsy) and follow-up time
using the SAS software package (version 8.0; SAS institute,
Cary, NC). Follow-up time was defined as the time from BBD
diagnosis to breast cancer diagnosis date (cases) or index
date (controls). Information on potential confounding variables
was obtained from responses on biennial questionnaires. For
each 2-year cycle of case–control selection, covariate informa-
tion was determined from the responses on questionnaires
Table 1
Cases and controls included in benign breast disease pathologic specimen collectiona
Cases Controls Selection of participants
1,080 4,353 Participants initially selected
-29 -85 Participant died or withdrew from study subsequent to selection
-265 -1,090 We did not pursue collection of specimens, because:
• participant denied having biopsy or had cyst aspiration only
• participant could not recall hospital or hospital no longer exists
• participant denied permission to seek specimens
• biopsy contained cancer
-379 -1,406 We were unable to obtain requested samples
• specimens were no longer available or destroyed
• hospital had no record of the patient or biopsy
• hospital had no record of the patient or biopsy
-33 -113 Specimens received were not usable for study
• slides were not of good quality/not evaluable
• specimens did not contain breast tissue
• were from wrong person or incorrect date
374 1,659 Eligible participants for whom we collected usable specimens
aNurses' Health Study I (1976 to 1994) and II (1989 to 1995).Breast Cancer Research    Vol 7 No 4    Tamimi et al.
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immediately preceding the cycle in which the breast cancer
case was diagnosed. In addition to matching factors and fol-
low-up interval, multivariate analyses were adjusted for the fol-
lowing confounders and breast cancer risk factors: first-
degree family history of breast cancer (yes/no); quartiles of
body mass index (≤  21.6, 21.7 to 23.6, 23.7 to 26.6, ≥  26.7
kg/m2); age at menarche (<12, 12, 13, ≥  14 years); age at first
birth/parity (nulliparous; one to four children, and age at first
birth if ≤  24 years of age; one to four children, and age at first
birth if >24 years of age; five or more children, and age at first
birth if ≤  24 years of age; five or more children age at first birth
>24); duration of postmenopausal hormone use (never, <5
years, ≥  5 years); and menopausal status/type of menopause
(premenopausal, natural, bilateral oopherectomy, other or
unknown type of menopause).
Analyses examining the combined effect of benign breast his-
tology and alcohol consumption were based on a cross-clas-
sified variable that used nonproliferative breast disease and
consumption of 0 g of alcohol per day as the reference group.
To examine whether the association between alcohol con-
sumption and breast cancer was modified by benign breast
histology, we conducted a likelihood ratio test to assess sta-
tistical significance of an interaction term using an ordered
scale for benign breast histology and alcohol consumption.
Results
Among the controls selected in this nested case–control
study, women with atypical hyperplasia were older at biopsy
and had their biopsies slightly later (1983 versus 1979) than
women with nonproliferative benign histology (Table 2).
Women with atypical hyperplasia had a greater prevalence of
family history of breast cancer and were less likely to be pre-
menopausal at benign biopsy than women with nonprolifera-
tive breast disease. In addition, recent alcohol consumption
was greatest for women with atypical hyperplasia and lowest
for women with nonproliferative breast disease (Table 2). This
result is unexpected, given that previous analysis in the NHS II
cohort indicated that recent alcohol consumption is not asso-
ciated with an increased risk of proliferative breast disease,
including atypical hyperplasia [13]. Adjusting for age did not
change the interpretation of the results in Table 2. For the
other breast cancer risk factors presented in Table 2, there
was no clear pattern of association with benign histology.
Overall, women with proliferative breast disease without atypia
had a 50% greater risk of breast cancer than women with non-
proliferative disease (OR = 1.54) (Table 3). Women with atyp-
ical hyperplasia had a more than fourfold increased risk of
breast cancer in comparison with women with nonproliferative
breast disease (OR = 4.43) (Table 3).
In this nested case–control study, there was no increased risk
of breast cancer among women drinking ≥  15 g of alcohol per
Table 2
Characteristics of controls in the nested case–control study according to benign breast disease category
Category of benign breast disease
Descriptive characteristic Nonproliferative Proliferative without atypia Atypical hyperplasia
Mean
Age at biopsy (y) 42.5 43.7 50.1
Year of biopsyb 1979 1980 1983
Age at menarche (y) 12.7 12.5 12.9
Age at first birthc (y) 24.8 24.9 25.0
Age at menopaused 46.6 46.5 47.2
Body mass index, kg/m2 25.1 24.6 24.5
Parity 2.8 2.7 2.9
Recent alcohol consumption, g/day 4.8 5.4 6.6
Frequency, %
Premenopausal at biopsy 76.5 76.1 57.1
Family history of breast cancer 11.2 13.3 18.3
Nulliparous 6.5 8.2 5.6
Natural menopause d 46.8 50.7 48.5
Bilateral oophorectomyd 20.1 16.8 17.5
aNurses' Health Study I (1976 to 1994) and II (1989 to 1995). bMedian. cAmong parous women only. dAmong postmenopausal women.Available online http://breast-cancer-research.com/content/7/4/R555
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day compared with nondrinkers (OR = 0.86; 95% CI 0.50 to
1.46).
The combined effects of alcohol consumption and category of
BBD histology are presented in Table 4. Among women with
nonproliferative BBD, recent alcohol consumption was posi-
tively associated with breast cancer risk: those consuming ≥
15 g of alcohol per day had a nonsignificant 67% increased
risk of breast cancer (OR = 1.67; 95% CI 0.65 to 4.34).
Among women with nonproliferative BBD, there was a 10%
increased risk of breast cancer per 5 g increase in daily alco-
hol consumption (OR = 1.10; 95% CI 0.95 to 1.27). Among
women with proliferative BBD without atypia, there was no
increased risk of breast cancer associated with a 5-g increase
in daily alcohol consumption (OR = 0.97; 95% CI 0.87 to
1.08). Similarly, among women with proliferative BBD with aty-
pia, there was no evidence that increasing alcohol consump-
tion increases risk: a 5-g increase in alcohol consumption was
associated with a nonsignificant 12% reduction in breast can-
cer risk (OR = 0.88; 95% CI 0.73 to 1.06). The interaction
between alcohol consumption and BBD category was not sta-
tistically significant (P = 0.20).
Analyses limited to invasive breast cancers (n = 232 cases)
showed similar results. We were limited in power to ade-
quately assess this relation according to menopausal status
and estrogen receptor status of the cancer.
Discussion
To our knowledge, this is the first study to prospectively exam-
ine the effects of alcohol with proliferative BBD in relation to
subsequent breast cancer risk. The results of this study indi-
cate that recent alcohol consumption does not increase the
risk of breast cancer to a greater extent among women with
proliferative BBD than in women with nonproliferative BBD.
Previous epidemiologic studies have examined the effect of
alcohol consumption among women with a self-report of BBD,
with inconsistent results [1,16-18]. In a cohort study
conducted in the Netherlands, van den Brandt and colleagues
reported a nonsignificant 2.5-fold increased risk of breast
cancer among women with BBD who drank ≥  15 g of alcohol
per day compared with nondrinkers (P for trend = 0.15) [16].
A pooled analysis of six cohort studies, including the Nether-
lands cohort just mentioned, reported no significant interac-
tion between alcohol consumption and BBD with respect to
breast cancer risk (P = 0.23) [1]. In the California Teachers
Study, the joint effect of history of BBD and high alcohol con-
sumption was associated with a twofold increased risk of
breast cancer (relative risk (RR) = 1.97; 95% CI 1.39 to 2.79),
while nondrinkers with biopsy-confirmed BBD had a 35%
increased risk of breast cancer (RR = 1.35; 95% CI 1.05 to
1.73) in comparison with nondrinkers with no history of BBD
[17].
Benign breast conditions are a heterogeneous group of dis-
eases and therefore may not all respond to alcohol exposure
in the same manner. Although all of the women in this study
had a biopsy removing their benign lesion, we were operating
under the assumption that the BBD is a marker of susceptibil-
ity and the remaining breast tissue may have a similar
susceptibly to the effects of alcohol later in life. Nonprolifera-
tive breast diseases comprise a large proportion of reported
BBD biopsies. The inconsistencies observed between our
study and previous studies may be due to the heterogeneous
nature of BBD and variability in distribution of BBD types
between different studies.
One proposed mechanism by which alcohol may influence
breast cancer risk is by increasing circulating estradiol levels,
as has been observed in controlled feeding studies in both
premenopausal and postmenopausal women [6,7]. A second
potential mechanism is that alcohol may function as a cocar-
cinogen, inhibiting detoxification of carcinogens, or by impair-
ing clearance of carcinogens [3,8-10]. There are data
suggesting that alcohol may act early in the carcinogenic proc-
ess [6-9], as well as later, functioning as a tumor promoter [3].
The current study failed to support our a priori hypothesis and
suggests that recent alcohol consumption does not contribute
additional risk to women with proliferative breast disease. One
explanation may be that women with proliferative breast dis-
eases are further along on the continuum to breast cancer, and
Table 3
Effect of category of benign breast disease histology on breast cancer riska
Benign breast disease category Cases No. (%) Controls No. (%) OR (95% CI)b OR (95% CI)c
Nonproliferative 69(24.5) 474 (38.8) 1.00 (Ref) 1.00 (Ref)
Proliferative without atypia 140 (49.7) 623 (50.9) 1.59 (1.16–2.18) 1.54 (1.12–2.11)
Atypical hyperplasia 73 (25.9) 126 (10.3) 4.54 (3.03–6.78) 4.43 (2.93–6.69)
Total 282 1,223
aNurses' Health Study I (1976 to 1994) and II (1989 to 1995). bAdjusted for age, year of biopsy, and follow-up interval. cAdjusted for age, year of 
biopsy, and follow-up interval, age at menarche, body mass index, weight change since age 18, age at first birth/parity, menopausal status/type of 
menopause, duration of postmenopausal hormone use. CI, confidence interval; OR, odds ratio; Ref, reference group for statistical comparisons.Breast Cancer Research    Vol 7 No 4    Tamimi et al.
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are already at an elevated risk of breast cancer, which is no
longer affected by alcohol. In contrast, women with nonprolif-
erative breast disease are not as far along the pathway to
breast cancer and specific exposures such as alcohol may
exhibit harmful effects and influence the risk of breast cancer.
Byrne and colleagues conducted a similar study in the Nurses'
Health Study to examine the effects of postmenopausal hor-
mone use among women with BBD [25]. Similarly, the results
were contrary to their a priori hypothesis and they observed no
elevated risk of breast cancer among women with proliferative
breast diseases according to current use of hormones or dura-
tion of use, again suggesting that these women may be at
such an increased risk of breast cancer that the additional
effect of exogenous hormone use is minimal or none.
In Figure 1, we have schematically described the evidence
relating alcohol exposure to breast cancer. It is well accepted
that recent alcohol consumption increases the risk of breast
cancer [1,16-18,26-28] and there is little evidence that alco-
hol intake early in life affects breast cancer risk [17,26-28].
The three studies examining alcohol and proliferative breast
disease suggest that recent alcohol intake does not increase
the risk of proliferative breast disease [13-15] and may in fact
be inversely related to it, with estimates ranging from a 10%
[13] to a 77% [14] reduction in risk comparing the highest cat-
egory of alcohol consumption with nondrinkers. These results,
along with those from the current study, suggest that the asso-
ciation observed between recent alcohol consumption and
breast cancer may not be mediated through proliferative
breast disease. However, Byrne and colleagues examined
alcohol consumption between the ages of 18 and 22 and pro-
liferative breast disease and reported a 30% increased risk
among women consuming ≥  15 g of alcohol per day compared
with nondrinkers (RR = 1.33, 95% CI 1.05 to 1.69) [13], sug-
gesting that only very early alcohol consumption may affect
proliferative BBD.
The progression from tumor initiation to breast cancer is not
well defined. One hypothesis is that the pathway from normal
Table 4
Combined effect of alcohol and category of benign breast disease histology on breast cancer riska
Jointly-classifiedb Stratifiedc>
Category of BBD Recent alcohol 
consumption (g/day)
Cases Controls OR (95% CI)d OR (95% CI)e OR (95% CI)d OR (95% CI)e
Nonproliferative
0 21 178 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
<5 27 165 1.41 (0.76–2.60) 1.42 (0.77–2.65) 1.34 (0.72–2.50) 1.46 (0.75–2.85)
5–15 14 95 1.27 (0.62–2.62) 1.25 (0.60–2.60) 1.31 (0.63–2.74) 1.15 (0.53–2.53)
≥  15 7 36 1.67 (0.66–4.27) 1.67 (0.65–4.34) 1.85 (0.71–4.84) 1.90 (0.67–5.39)
P for trendf 0.13 0.20
Proliferative without atypia
0 46 205 2.04 (1.17–3.57) 1.99 (1.13–3.50) 1.00 (Ref) 1.00 (Ref)
<5 52 235 1.91 (1.11–3.29) 1.82 (1.05–3.16) 0.99 (0.63–1.55) 0.99 (0.62–1.56)
5–15 34 123 2.43 (1.34–4.41) 2.40 (1.31–4.39) 1.17 (0.70–1.94) 1.14 (0.67–1.91)
≥  15 8 60 1.15 (0.48–2.75) 1.09 (0.45–2.62) 0.59 (0.26–1.33) 0.61 (0.26–1.41)
P for trendf 0.49 0.58
Proliferative with atypia
0 23 40 5.57 (2.77–11.21) 5.58 (2.74–11.38) 1.00 (Ref) 1.00 (Ref)
<5 30 45 6.65 (3.43–12.90) 6.48 (3.31–12.70) 1.28 (0.62–2.67) 1.29 (0.60–2.78)
5–15 14 25 5.35 (2.39–12.01) 5.26 (2.30–12.04) 1.03 (0.42–2.51) 1.02 (0.39–2.68)
≥  15 6 16 3.65 (1.27–10.47) 3.46 (1.19–10.09) 0.66 (0.22–1.97) 0.59 (0.19–1.89)
P for trendf 0.21 0.17
aNurses' Health Study I (1976 to 1994) and II (1989 to 1995). b Joint classification of BBD category and alcohol consumption where the reference 
group is women with nonproliferative BBD and 0 alcohol consumption. c The analysis is stratified by type of BBD where the reference group is 
women with 0 alcohol consumption within each category of BBD. dAdjusted for age at diagnosis, year of biopsy, and follow-up interval. eAdjusted 
for age at diagnosis, year of biopsy, and follow-up interval, age at menarche, body mass index quartiles, family history of breast cancer, parity/age at 
first birth, menopausal status/type of menopause, duration of postmenopausal hormone use. fTest for trend based on Wald test for continuous 
alcohol consumption. BBD, benign breast disease; CI, confidence interval; OR, odds ratio; Ref, reference group for statistical comparisons.Available online http://breast-cancer-research.com/content/7/4/R555
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tissue to breast cancer arises from a series of preinvasive
lesions: benign proliferative changes, atypical hyperplasia, and
carcinoma  in situ. If all breast cancers arise from benign
lesions, the results of this study, in conjunction with other data,
imply that there may be a narrow window of time when alcohol
consumption affects breast cancer risk. An alternative
explanation may be that there are multiple pathways to breast
cancer and pathways involving proliferative benign breast
lesions may not be influenced by alcohol consumption. A third
possibility is that the magnitude of risk associated with benign
proliferative lesions, and in particular atypical hyperplasia, is so
much greater than the effect of alcohol that we were under-
powered to detect more subtle increases in risk attributable to
alcohol in this study.
Although this is one of the largest studies of its kind, the
number of women with proliferative breast disease and high
alcohol consumption was small. We were underpowered to
examine this relation in greater detail with regard to
menopausal status and estrogen receptor status of tumors. A
potential concern of the study is that the final study population
represents 37% of those originally selected. The study proto-
col required collection of pathologic specimens in order to
have unified review of histologic sections. The major limitation
of this is that many hospitals routinely destroy specimens after
5 or 10 years. As a result, many potential cases and controls
were excluded, which could result in potential selection bias.
There were no significant differences in reasons for loss com-
paring cases to controls, indicating that any differences that
do occur are likely to be due to chance.
Conclusion
In this study, we observed that women with proliferative BBD
experienced no additional risk of breast cancer with increased
alcohol consumption. It remains unclear whether alcohol acts
early, acts late, or has multiple effects on breast cancer risk.
Future studies with greater numbers should examine meno-
pausal and hormone receptor status of the cancers in order to
provide additional information on both timing of relevant expo-
sure and biologic mechanisms.
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